Back to Atlas
BSemi-durableStandard research/education caution
CMP-0696
Research chemical/reference listing
TT-232
Immune modulation
Immune balance, inflammation, or resilience support
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Immune / inflammatory modulator
- Primary mechanism
- Immune or inflammatory pathway modulation
- Primary market use
- Immune modulation
Pharmacology
- Molecular weight (Da)
- 947.13
- Oral bioavailability
- Route-dependent / verify
- Half-life
- ~5–60 min parent peptide; analogs may be longer
- Route tags
- SubQ; Injectable; route-dependent
- Evidence level
- MCE product listing / research chemical signal
- Clinical status
- Research chemical/reference listing
- Value-for-money score
- 7 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis . TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent.